Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Autoantibodies (aAbs) to type I interferons (IFNs) have been found in less than 1% of individuals under the age of 60 in the general population, with the prevalence increasing among those over 65. Neutralizing autoantibodies (naAbs) to type I IFNs have been found in at least 15% of patients with life-threatening COVID-19 pneumonia in several cohorts of primarily European descent. We aimed to evaluate the prevalence of aAbs and naAbs to IFN-α2 or IFN-ω in Japanese patients who suffered from COVID-19 as well as in the general population.
Methods: Patients who suffered from COVID-19 (n = 622, aged 0-104) and an uninfected healthy control population (n = 3,456, aged 20-91) were enrolled in this study. The severities of the COVID-19 patients were as follows: critical (n = 170), severe (n = 235), moderate (n = 112), and mild (n = 105). ELISA and ISRE reporter assays were used to detect aAbs and naAbs to IFN-α2 and IFN-ω using E. coli-produced IFNs.
Results: In an uninfected general Japanese population aged 20-91, aAbs to IFNs were detected in 0.087% of individuals. By contrast, naAbs to type I IFNs (IFN-α2 and/or IFN-ω, 100 pg/mL) were detected in 10.6% of patients with critical infections, 2.6% of patients with severe infections, and 1% of patients with mild infections. The presence of naAbs to IFNs was significantly associated with critical disease (P = 0.0012), age over 50 (P = 0.0002), and male sex (P = 0.137). A significant but not strong correlation between aAbs and naAbs to IFN-α2 existed (r = - 0.307, p value < 0.0001) reinforced the importance of measuring naAbs in COVID-19 patients, including those of Japanese ancestry.
Conclusion: In this study, we revealed that patients with pre-existing naAbs have a much higher risk of life-threatening COVID-19 pneumonia in Japanese population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243824 | PMC |
| http://dx.doi.org/10.1007/s10875-022-01308-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Salivary autoantibodies to type I IFNs: Mirror plasma levels, predispose to severe COVID-19, and enhance feasibility for clinical screening.
Heart Lung
May 2024
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Prince Abdullah Ben Khaled Celiac Disease Research Chair, department of pediatrics, Fa
Background: Autoantibodies have been demonstrated to dampen the interferon (IFN) response in viral infections. Elevated levels of these preexisting autoantibodies (aAbs) decrease basal interferon levels, increasing susceptibility to severe infections.
Objectives: This study aimed to evaluate the prevalence of type I IFN aAbs in both plasma and saliva from COVID-19 patients, analyze their neutralizing activity, and examine their associations with clinical outcomes, including the need for mechanical ventilation and in-hospital mortality.
Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19.
J Clin Immunol
October 2022
Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Science, 1-2-3 Kasumi, Minami-Ku, Hiroshima-Shi, Hiroshima, 734-8551, Japan.
Article Synopsis
- A study evaluated the prevalence of autoantibodies (aAbs) and neutralizing autoantibodies (naAbs) to type I interferons in Japanese COVID-19 patients and a healthy control group.
- Among uninfected individuals in the general Japanese population, only 0.087% had aAbs, whereas 10.6% of critically ill patients had naAbs.
- The presence of naAbs was significantly linked to critical illness, older age, and male sex, indicating a greater risk for severe COVID-19 in those with pre-existing naAbs.
Article Synopsis
- The study investigates the prevalence of autoantibodies (aAbs) and neutralizing autoantibodies (naAbs) to type I interferons (IFNs) among Japanese individuals, noting a rare occurrence in the general population but higher rates in older adults and critically ill COVID-19 patients.
- Out of 3,456 healthy Japanese controls, only 0.087% had aAbs, while in the 627 COVID-19 patients studied, naAbs were significantly present in 10.6% of critical cases and in lower percentages for severe cases.
- Results show that older COVID-19 patients (especially men) had higher naAb prevalence, suggesting a link between pre-existing naAbs and increased risk for severe
Human monoclonal natural autoantibodies against the T-cell receptor inhibit interleukin-2 production in murine T cells.
Immunology
April 2002
Department of Microbiology and Immunology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
Natural autoantibodies (NAAbs) specific for the T-cell receptor (TCR) are present in all human sera, but individuals with rheumatoid arthritis (RA) generally produce higher titres of immunoglobulin M (IgM) isotype autoantibodies (AAbs) against Vbeta TCR epitopes. To investigate possible correlations between the specificity of such AAbs and their role in immunomodulation, we generated seven B-cell hetero-hybridomas, secreting monoclonal IgM NAAbs, from the synovial tissue and peripheral blood of patients with RA. Here we report three anti-TCR monoclonal autoantibodies (mAAbs)--OR2, OR5 and Syn 2H-11--with the ability to bind subsets of murine T cells, including the ovalbumin-specific DO-11.
View Article and Find Full Text PDF